ARCHIVES

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

This article is from The Cancer Letter archive.

Vol. 35 No. 31 | August 7, 2009

Download PDF Visit The Full Archive

Related Articles

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

DRCCA Board Fails To Agree on New Guidelines For Cancer Control Core Grants, Will Try Again

June 25, 1981

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

Promising Results For Glivec In CML Continue, FDA Grants Priority Review

April 27, 2001

NIH review finds 44 scientists violated ethics rules on industry consulting, House committee chairman says.

July 15, 2005

ACS Urges Bush To Increase NCI Budget.

January 19, 2007